Latest market price
17.61
+0.22+1.27%
OverviewShort InterestFilings
REPLQT92Replimune Group, Inc.·NASDAQ
17.61+1.27%
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
KLRA-4.10%$12.86NUVB-0.21%$4.76NVAX-3.72%$10.08STOK-0.23%$26.29TRAX-0.33%$45.08QURE-1.86%$24.83MLYS-14.41%$18.18NTLA-5.74%$12.47
Snapshot
Index—P/E—EPS (ttm)-2.79Insider Own27.80%Shs Outstand94.80MPerf Week53.66%
Market Cap1.67BForward P/E—EPS next Y-1.36Insider Trans9.68%Shs Float89.16MPerf Month30.93%
Enterprise Value1.48BPEG—EPS next Q—Short Float25.98%Perf Quarter47.86%
Income-271.00MP/S—EPS this Y—Short Ratio5.60Perf Half Y604.40%
Sales0.00P/B8.14EPS next Y—ROA-72.48%Short Interest23.17MPerf YTD81.17%
Book/sh2.16P/C5.42EPS next 5Y—ROE-157.78%52W High18.27 -3.61%Perf Year72.48%
Cash/sh3.25P/FCF—EPS past 3/5Y—ROIC-80.89%52W Low1.50 1074.00%Perf 3Y25.70%
Dividend Est.—EV/EBITDA—Sales past 3/5Y—Gross Margin0.00%Volatility13.99% 7.67%Perf 5Y-39.30%
Dividend TTM—EV/Sales—EPS Y/Y TTM—Oper. Margin0.00%ATR (14)1.12Perf 10Y—
Dividend Ex-Date—Quick Ratio6.90Sales Y/Y TTM—Profit Margin0.00%RSI (14)75.11Recom2.33
Dividend Gr. 3/5Y—Current Ratio7.11EPS Q/Q40.00%SMA2035.74%Beta0.92Target Price24.75
Payout0.00%Debt/Eq0.60Sales Q/Q—SMA5029.68%Rel Volume1.34Prev Close17.39
Employees465LT Debt/Eq0.60EarningsFeb 02SMA20089.48%Avg Volume2.87MPrice17.61
IPO DateJul 20, 2018Option/ShortYes / YesEPS/Sales Surpr.31.12% —Net Debt/EBITDA—Volume3,851,818Change1.27%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-29-26ReiteratedLeerink PartnersOutperform$17 → $31
Oct-28-26ReiteratedJefferiesHold$24 → $29
Aug-07-26ReiteratedBMO CapitalMarket Perform$16 → $20
Aug-07-26UpgradeWedbushNeutral → Outperform$12 → $19
Aug-04-26UpgradeLeerink PartnersMarket Perform → Outperform$34 → $17
Jul-31-26UpgradeCantor FitzgeraldNeutral → Overweight
Jul-31-26ReiteratedWedbushNeutral$9.00 → $12
Jun-30-26ReiteratedBMO CapitalMarket Perform$11 → $16
Jun-30-26ReiteratedWedbushNeutral$18 → $9.00
Jun-26-26UpgradeJP MorganNeutral → Overweight
Latest News· Times ET
Oct-28-26
Oct-28-2609:13PM
Replimune: 3 Key Takeaways for Long-Term Investorsfool.com
05:50PM
Replimune Group, Inc. (REPL) Q2 2027 Earnings Call Transcriptseekingalpha.com
07:00AM
Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Updateglobenewswire.com
04:57AM
Replimune Group Q2 2027 Earnings Call TranscriptBenzinga
Oct-22-26
Oct-22-2608:00AM
Replimune to Report the Fiscal Second Quarter 2027 Financial Results and Provide Corporate Update on October 28, 2026globenewswire.com
Oct-17-26
Oct-17-2612:14PM
Replimune Group (REPL) Stock Looks Rich After A 141% RunYahoo
Oct-13-26
Oct-13-2601:55PM
Replimune Group: A Hold Until TUDRIQEV's Commercial Potential Becomes ClearSeekingAlpha
Oct-09-26
Oct-09-2611:12AM
Replimune Group (REPL) Launches TUDRIQEV As Its Valuation Story Comes Into FocusYahoo
Oct-05-26
Oct-05-2612:19PM
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in Replimune Group, Inc. Lawsuit - REPLglobenewswire.com
12:00PM
Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harmglobenewswire.com
Oct-02-26
Oct-02-2602:44PM
REPLIMUNE CLASS ACTION DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Urgently Reminds Replimune Group Inc. Investors to Contact the Firm Seeking Lead Plaintiff Role Before October 5thglobenewswire.com
Oct-01-26
Oct-01-2604:01PM
Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanomaglobenewswire.com
12:00PM
Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harmglobenewswire.com
10:09AM
SueWallSt Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026 - REPLprnewswire.com
10:00AM
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPLprnewswire.com
Company

Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2026
3/31/2026
FY 2025
3/31/2025
FY 2024
3/31/2024
FY 2023
3/31/2023
FY 2022
3/31/2022
FY 2021
3/31/2021
FY 2020
3/31/2020
FY 2019
3/31/2019
Total Revenue
0000—————
Cost of Goods Sold Incl. D&A
0000—————
Gross Profit
0000—————
Selling, General and Administrative Excl. Other1149900—————
Research and Development188221189175—————
Other Operating Expense-3307360—————
Operating Income-269-320-262-235—————
Interest Expense12987—————
Unusual Expense
—————————
Non-Operating Income (Expense)10142326—————
Net Income Before Taxes-271-314-247-215—————
Income Taxes0-100—————
Consolidated Net Income-271-314-247-216—————
Net Income From Continuing Operations-270-314-247-216—————
Net Income-271-314-247-216—————
EPS (Recurring)-2.79-3.38-3.07-3.24—————
EPS (Basic, Before Extraordinaries)-2.79-3.38-3.07-3.24—————
EPS (Diluted)-2.79-3.38-3.07-3.24—————
EBITDA-259-302-256-230—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio
—————————
Gross Margin
—————————
Operating Margin
—————————
Net Margin
—————————
Shares Outstanding105938167—————
Market Capitalization1,849711790547—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$20.00$14.83$9.65$4.48$-0.69● Close Price0.00M0.26M0.52M0.78M1.04MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Hill Emily LuisaChief Financial OfficerAug 17 '26Sale14.289,256132,176215,852Aug 19
Patel SushilChief Executive OfficerAug 10 '26Sale12.9739,341510,253708,151Aug 12
Schwendenman AndrewChief Accounting OfficerAug 10 '26Sale12.977,63298,98799,425Aug 12
Xynos KonstantinosChief Medical OfficerAug 10 '26Sale12.9711,447148,468224,215Aug 12
Hill Emily LuisaChief Financial OfficerAug 10 '26Sale12.9711,448148,481225,108Aug 12
BAKER BROS. ADVISORS LPDirector, 10% OwnerAug 11 '26Buy0.002,736,3402742,609,946Aug 11
Sarchi ChristopherChief Commercial OfficerJun 01 '26Sale9.2412,000110,880180,962Jun 03
Patel SushilChief Executive OfficerMay 18 '26Sale5.0837,324189,606747,492May 20
Astley-Sparke PhilipDirectorMay 18 '26Sale5.0817,65789,6981,412,414May 20
Hill Emily LuisaChief Financial OfficerMay 18 '26Sale5.087,81239,685236,556May 20
Schwendenman AndrewChief Accounting OfficerMay 18 '26Sale5.087,89440,102107,057May 20
Xynos KonstantinosChief Medical OfficerMay 18 '26Sale5.0814,02371,237235,662May 20
Sarchi ChristopherChief Commercial OfficerMay 18 '26Sale5.088,62643,820192,962May 20
Sarchi ChristopherChief Commercial OfficerApr 02 '26Sale8.016,50052,065151,588Apr 06
Dhingra KapilDirectorDec 09 '25Option Exercise1.753,1695,5463,169Dec 11
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.